Theoretically. Yes. Some on this message board discussed such a possibility years ago. For instance, an inoperable tumor using both DCVax-l made from biopsy tissue, whilst injecting the remaining tumor with DCVax-Direct.
The problem has been how long it’s taken to get DCVax-l to market and DCVax-Direct to a pivotal trial. It’s agonizingly slow. Hopefully, L will demonstrate success in the now long completed phase iii trial and be approved soon.
News 
Market Data 
Discover 
AI
